Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study

Thrombosis Research
Jonathan DouxfilsFrançois Mullier

Abstract

Dilute Russell Viper Venom Time (DRVV-T) might be useful in urgent settings for screening patients on Non-VKA Oral Anticoagulants (NOACs). To compare the accuracy of DRVV-T with gold standard assays for the assessment of pharmacodynamics of dabigatran, rivaroxaban and vitamin K antagonist (VKA) in plasma samples from patients. Sixty rivaroxaban, 48 dabigatran and 50 VKA samples from patients were included. DRVV-T was performed in all groups using STA®-Staclot®DRVV-Screen and -Confirm. For NOACs, PT and aPTT were performed using different reagents while plasma drug concentrations were measured by liquid mass-spectrometry (LC-MS/MS). For VKA, INR was performed using RecombiPlasTin 2G®. For NOACs, correlations between calibrated STA®-Staclot®DRVV-Confirm and LC-MS/MS (rs=0.88 and 0.97 for rivaroxaban and dabigatran, respectively) were higher than the ones obtained with STA®-Staclot®DRVV-Screen (rs=0.87 and 0.91), PT (rs=0.83 to 0.86) or aPTT (rs=0.84 to 0.89). Bland Altman analyses showed that calibrated DRVV-T methods tend to overestimate plasma concentrations of NOACs. ROC curves revealed that cut-off to exclude supra-therapeutic levels at Ctrough (i.e. 200ng/mL) are different for dabigatran and rivaroxaban. Neither STA®-Staclot...Continue Reading

References

Aug 5, 2008·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·G Rohde
Feb 6, 2010·Thrombosis and Haemostasis·Meyer Michel SamamaElisabeth Perzborn
Jun 15, 2011·Journal of Thrombosis and Haemostasis : JTH·G M A van OsPh G de Groot
Mar 23, 2012·Thrombosis and Haemostasis·Hugo Ten Cate
Aug 8, 2012·The American Journal of Emergency Medicine·Ami SchattnerJoshua Friedman
Feb 1, 2013·Thrombosis and Haemostasis·Thomas ExnerAileen Barancewicz
Apr 30, 2013·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Hein HeidbuchelUNKNOWN European Heart Rhythm Association
Jun 21, 2013·European Journal of Clinical Pharmacology·Jovan P AntovicRickard E Malmström
Sep 4, 2013·Clinical Pharmacokinetics·Wolfgang MueckMichael Becka
Feb 7, 2014·Seminars in Thrombosis and Hemostasis·Gary W Moore
Jul 25, 2014·BMJ : British Medical Journal·Deborah Cohen

❮ Previous
Next ❯

Citations

Oct 17, 2015·Expert Review of Cardiovascular Therapy·Noel C ChanJohn W Eikelboom
Nov 1, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Steen HustedWillemijn J Comuth
Apr 15, 2016·Thrombosis and Haemostasis·Franz RatzingerPeter Quehenberger
Mar 1, 2016·Journal of Thrombosis and Haemostasis : JTH·L R LetertreP T Onundarson
Jul 6, 2017·Hämostaseologie·Robert C GosselinDorothy Adcock
Feb 28, 2018·European Journal of Haematology·Jackie Pratt, Philip Crispin
Oct 23, 2015·British Journal of Haematology·Brian J DaleJohn W Eikelboom
May 19, 2017·Thrombosis Journal·Virginie DuboisSarah Lessire
Jan 31, 2019·British Journal of Haematology·Jignesh P PatelRoopen Arya
Aug 13, 2021·Seminars in Thrombosis and Hemostasis·Gary William Moore

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.